Kerin . (2014) Lobular Breast Cancer in a CDH1 Splice Site Mutation Carrier: Case Report and Review of the Literature. Clinical Breast Cancer 14 , e47-e51 Online publication date: 1-Apr-2014. /McVeigh TP, Choi JK, Miller NM, Green AJ and Kerin MJ: Lobular breast cancer ...
Worldwide, breast cancer is the leading cause of cancer-related deaths in women. Breast cancer is a heterogeneous disease characterized by different clinical outcomes in terms of pathological features, response to therapies, and long-term patient surviva
First-generation molecular profiles for human breast cancers have enabled the identification of features that can predict therapeutic response; however, little is known about how the various data types can best be combined to yield optimal predictors. Co
CDH1is located on chromosome 16q22 and codes for the E-cadherin protein. E-cadherin maintains tissue integrity as it mediates cell-cell adhesion. There is also evidence that forced expression of the protein inhibits the growth of breast cancer cells via mechanisms that are yet to be determined,...
The Human Breast Cancer qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate, and comprehensive profiling of the top somatic mutations in human breast cancer samples in the following genes: AKT1, APC, BRAF, CDH1, CTNNB1, HRAS, KRAS, NRAS, PIK3CA,...
Breast cancer is the most frequent cancer among women. Genetics are the main risk factor for breast cancer. Statistics show that 15–25% of breast cancers are inherited among those with cancer-prone relatives. BRCA1, BRCA2, TP53, CDH1, PTEN, and STK11 ar
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adop
There are other high penetrance gene mutations associated with breast cancer, but BRCA1 and BRCA2 are best elucidated [24]. Other high-penetrance genes include PTEN, TP53, STK11, and CDH1 [25], PALB2 [26], ATM and CHEK2 ([24,27]). Mutation in PALB2 is associated with an increased...
Breast cancer is the most common malignancy in women, accounting for about 270,000 cases a year. The average woman has about a 12% chance of developing breast cancer.
2.Eribulin for Advanced Breast Cancer: A Drug Evaluation 机译:依立布林用于晚期乳腺癌的药物评价 作者:Alaaeldin Shablak 期刊名称:《Journal of Breast Cancer》 | 2013年第1期 关键词: Breast neoplasms Eribulin Microtubule inhibitor; 3.The Role of the CDH1 Promoter Hypermethylation in the Axillary...